Vaginal micronized progesterone in continuous hormone replacement therapy. A prospective randomized study.

Authors: Ferrero S, Gerbaldo D, Fulcheri E, Cristoforoni P.

Publication Year: 2002

Citation: Minerva Ginecol 2002; 54(6):519-30.

Transvaginal micronized progesterone (100 mg/day for 12 days/month) effectively promoted a functional, secretory endometrium, while cyclic oral medroxyprogesterone acetate or transdermal norethisterone acetate more often produced endometrial atrophy, in women receiving continuous transdermal estradiol.

http://www.ncbi.nlm.nih.gov/pubmed/12432337